



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
|-----------------|-------------|----------------------|---------------------|------------------|

10/570,904

06/06/2006

Seiji Takeshima

251134

1646

23460

7590

03/24/2008

LEYDIG VOIT & MAYER, LTD
TWO PRUDENTIAL PLAZA, SUITE 4900
180 NORTH STETSON AVENUE
CHICAGO, IL 60601-6731

EXAMINER

PAK, YONG D

ART UNIT

PAPER NUMBER

1652

MAIL DATE

DELIVERY MODE

03/24/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| | | | |
|------------------------------|--------------------------------------|---|--|
| Office Action Summary | Application No. 10/570,904 | Applicant(s) TAKESHIMA ET AL. | |
| | Examiner Yong D. Pak | Art Unit 1652 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 25 January 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-18 is/are pending in the application.
- 4a) Of the above claim(s) 3 and 5-18 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 2 and 4 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 3/7/06 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>6/11/07&3/7/06</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

This application is a 371 of PCT/JP04/12508.

The preliminary amendment filed on March 7, 2006, amending claims 5 and 9-11 and adding claims 12-18, has been entered.

Claims 1-18 are pending. Claims 3 and 5-18 withdrawn. Claims 1-2 and 4 are under consideration.

Election/Restrictions

Applicant's election with traverse of Group I (claims 1, 2, and 4) in the reply filed on January 25, 2008 is acknowledged. The traversal is on the ground(s) that the claims of Group I and the claims of Groups II-V are sufficiently similar that the search and examination of the claims of Group I would likely overlap the search and examination of the claims of Groups II-V, as a result of which the Examiner would incur no undue burden in examining the claims of Groups I-V at the same time as discussed in MPEP 803. This is not found persuasive because the instant application is a national stage of a PCT application and Unity of Invention under PCT applies, not Restriction Practice. Therefore, section 803 of the MPEP does not apply. Further, under Unity of Invention, if the technical featuring linking the inventions does not define a contribution over the prior art, there is lack of unity amongst the inventions, which is the case in the instant application.

The requirement is still deemed proper and is therefore made FINAL.

Claims 3 and 5-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on January 25, 2008.

Information Disclosure Statement

The information disclosure statements (IDS) submitted on June 11, 2007 and March 7, 2006 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner.

Claim Objections

Claim 4 is objected to because said claims depend from non-elected claim. However, in order to expedite the prosecution, Examiner has taken into consideration the subject matter of claim 3 in order to examine claim 4. Appropriate correction, incorporating the limitations of the non-elected claim, into claim 4 is requested.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1-2 and 4 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a non-statutory subject matter.

Claims 1-2 and 4, as written, do not sufficiently distinguish over PQQGDH as they exist naturally because the claims do not particularly point out any non-naturally occurring differences between the claimed products and the naturally occurring products, such as being “isolated”. Even though the claims are drawn to modified/mutant PQQGDH, such mutants can exist naturally. In the absence of the hand of man, the naturally occurring products are considered non-statutory subject matter. See *Diamond v. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (1980). The claims should be amended to indicate the hand of the inventor, e.g., by insertion of “isolated” as taught by the specification. See MPEP 2105.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1 and claims 2 and 4 depending therefrom are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 recites the phrase “lower action property on disaccharide”. The metes and bounds of this phrase in the context of the claims are not clear to the Examiner. The phrase encompasses many different “actions” and “properties” on disaccharide and is outside the scope of the invention. A perusal of the specification did not provide the

Art Unit: 1652

Examiner with a specific definition for the above phrase. Therefore, it is not clear to the Examiner either from the specification or from the claim as to what specific “action property” are encompassed in the above phrase. It is suggested that applicants clarify the meaning of the activity of the mutant polypeptide. Examiner requests clarification of the above phrase.

Further, it is not clear to the Examiner as to how much of a decrease in the “action property” on a disaccharide compared to wild type enzyme is considered as “lower action property” by the applicants. A perusal of the specification did not provide a clear definition for the above phrase. Without a clear definition in terms of numerical value, those skilled in the art would be unable to conclude what is “lower action property”.

Claims 2 and 4 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 2 and 4 recite the phrase “more enhanced stability” or “more enhanced specific activity”. The metes and bounds of this phrase in the context of the claims are not clear to the Examiner. The phrase encompasses many different “stabilities” (thermal, enzymatic, pH, etc) which can be considered as “stability” and is outside the scope of the invention. A perusal of the specification did not provide the Examiner with a specific definition for the above phrase. Therefore, it is not clear to the Examiner either from the specification or from the claim as to what specific stability of the polypeptide

are encompassed in the above phrase. It is suggested that applicants clarify the meaning of the stability of the mutant polypeptide. Examiner requests clarification of the above phrase.

Further, it is not clear to the Examiner as to how much of an increased on the stability or specific activity of the mutant polypeptide compared to wild type enzyme is considered as "more enhanced" by the applicants. A perusal of the specification did not provide a clear definition for the above phrase. Without a clear definition in terms of numerical value, those skilled in the art would be unable to conclude what is "more enhanced".

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-2 and 4 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1-2 and 4 are drawn to modified PQQGDH having a lower action property on disaccharide and/or more enhanced stability/specific activity than the wild type PQQGDH. It is noted that MPEP 2111.01 states that "[d]uring examination, the claims

must be interpreted as broadly as their terms reasonably allow." The claims encompass any or all variants, mutants and recombinants of any PQQGDH isolated from any source, wherein said PQQGDH has a lower action property on disaccharide and/or more enhanced stability/specific activity than the wild type PQQGDH from which said PQQGDH is derived from or any other wild type PQQGDH. Therefore, the claims are drawn to a genus of modified PQQGDH having any structure, including any or all recombinants, mutants and variants of PQQGDH isolated from any source, wherein said modified PQQGDH has a lower action property on disaccharide and/or more enhanced stability/specific activity than any wild type PQQGDH.

In *University of California v. Eli Lilly & Co.*, 43 USPQ2d 1938, the Court of Appeals for the Federal Circuit has held that "A written description of an invention involving a chemical genus, like a description of a chemical species, 'requires a precise definition, such as by structure, formula, (or) chemical name,' of the claimed subject matter sufficient to distinguish it from other materials". As indicated in MPEP 2163, the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show that Applicant was in possession of the claimed genus. In addition, MPEP 2163 states that a representative number of species means that the species which are adequately described are

representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus.

The recitation of “modified PQQGDH” having “a lower action property on disaccharide” and/or “more enhanced stability/specific activity than the wild type PQQGDH” fails to provide a sufficient description of the claimed genus of proteins as it merely describes the functional features of the genus without providing any definition of the structural features of the species within the genus. The CAFC in *UC California v. Eli Lilly*, (43 USPQ2d 1398) stated that: “in claims to genetic material, however a generic statement such as ‘vertebrate insulin cDNA’ or ‘mammalian insulin cDNA,’ without more, is not an adequate written description of the genus because it does not distinguish the claimed genus from others, except by function. It does not specifically define any of the genes that fall within its definition. It does not define any structural features commonly possessed by members of the genus that distinguish them from others. One skilled in the art therefore cannot, as one can do with a fully described genus, visualize or recognize the identity of the members of the genus.” Similarly with the claimed genus of “modified PQQGDH”, the functional definition of the genus does not provide any structural information commonly possessed by members of the genus which distinguish the protein species within the genus from other proteins such that one can visualize or recognize the identity of the members of the genus.

The claims are drawn to modified PQQGDH having any structure, including any or all recombinants, mutants and variants of PQQGDH isolated from any source,

wherein said modified PQQGDH has a lower action property on disaccharide and/or more enhanced stability/specific activity than any wild type PQQGDH. The specification only describes one representative species, specific PQQGH variants (Q168A+L169(G or P)+E245D) of a single PQQGDH having the amino acid sequence of SEQ ID NO:1, wherein said variants have the properties recited in claims 1-2 and 4. While MPEP 2163 acknowledges that in certain situations “one species adequately supports a genus,” it also acknowledges that “[f]or inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus.” In view of the widely variant species encompassed by the genus, a few mutants of a single species of PQQGDH (SEQ ID NO:1) are not enough and does not constitute a representative number of species to describe the whole genus of any or all variants, recombinant and mutants of any or all PQQGDH isolated from any source and there is no evidence on the record of the relationship between the structure of SEQ ID NO:1 and the structure of any or all PQQGDH isolated from any source, including any or all recombinants, variants and mutants. Therefore, the specification fails to describe a representative species of the genus comprising any or all variants, mutants and recombinants of any PQQGDH isolated from any source.

Given this lack of description of the representative species encompassed by the genus of the claims, the specification fails to sufficiently describe the claimed invention in such full, clear, concise, and exact terms that a skilled artisan would recognize that applicants were in possession of the inventions of claims 1-2 and 4.

Applicant is referred to the revised guidelines concerning compliance with the written description requirement of U.S.C. 112, first paragraph, published in the Official Gazette and also available at www.uspto.gov.

Claims 1-2 and 4 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for specific variants of PQQGDH of SEQ ID NO:1 (Q168A+L169(G or P)+E245D), wherein said variants have the properties recited in claims 1-2 and 4, does not provide enablement for modified PQQGDH having any structure. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Factors to be considered in determining whether undue experimentation is required are summarized in In re Wands 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir. 1988). They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

Claims 1-2 and 4 are drawn to modified PQQGDH having a lower action property on disaccharide and/or more enhanced stability/specific activity than the wild type PQQGDH.

The breadth of the claims.

It is noted that MPEP 2111.01 states that "[d]uring examination, the claims must be interpreted as broadly as their terms reasonably allow." The claims encompass any or all variants, mutants and recombinants of any PQQGDH isolated from any source, wherein said PQQGDH has a lower action property on disaccharide and/or more enhanced stability/specific activity than the wild type PQQGDH from which said PQQGDH is derived from or any other wild type PQQGDH. Therefore, the claims are drawn to any or all modified PQQGDH having any structure, including any or all recombinants, mutants and variants of PQQGDH isolated from any source, wherein said modified PQQGDH has a lower action property on disaccharide and/or more enhanced stability/specific activity than any wild type PQQGDH. Hence, the claims encompass PGGGDH having any structure.

The scope of the claims is not commensurate with the enablement provided by the disclosure with regard to the extremely large number of polypeptides of virtually any structure. In the instant case, the specification only enables specific PQQGH variants (Q168A+L169(G or P)+E245D) of a single PQQGDH having the amino acid sequence of SEQ ID NO:1, wherein said variants have the properties recited in claims 1-2 and 4.

The quantity of experimentation required to practice the claimed invention based on the teachings of the specification.

While enzyme isolation techniques, recombinant and mutagenesis techniques were known in the art at the time of the invention, e.g. mutagenesis, and it is routine in the art to screen for variants comprising multiple substitutions or multiple modifications as encompassed by the instant claims, the specific amino acid positions within the

Art Unit: 1652

protein's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining the desired activity/utility are limited in any protein and the result of such modifications is unpredictable. In addition, one skilled in the art would expect any tolerance to modification for a given protein to diminish with each further and additional modification, e.g. multiple substitutions.

In the absence of: (a) rational and predictable scheme for modifying any amino acid residue with an expectation of obtaining the desired biological function, (b) a correlation between structure and function of cellulolytic activity, the specification provides insufficient guidance as to which of the essentially infinite possible choices is likely to be successful. One of skill in the art would have to test these infinite possible polypeptides to determine (1) which mutants have PGGGDH activity, (2) the specific substrates targeted by such proteins and (3) how to use those polypeptides not having PGGGDH activity. While enablement is not precluded by the necessity for routine screening, if a large amount of screening is required, as is the case herein, the specification must provide a reasonable amount of guidance which respect to the direction in which the experimentation should proceed so that a reasonable number of species can be selected for testing. In view of the fact that such guidance has not been provided in the instant specification, it would require undue experimentation to enable the full scope of the claims

The state of prior art, the relative skill of those in the art, and predictability or unpredictability of the art.

Since the amino acid sequence of the mutant determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and obtain the desired activity requires a knowledge of and guidance with regard to which amino acids in the protein's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the proteins' structure relates to its function. In the instant case, neither the specification or the art provide a correlation between structure and activity such that one of skill in the art can envision the structure of any polypeptides having the same biological function as that of the polypeptide of SEQ ID NO:1 or predict the function of a polypeptide from its primary structure. In addition, the art does not provide any teaching or guidance as to (1) which amino acids within the polypeptides of SEQ ID NO:1 (other than the amino acid at positions 168, 169 and 245 of SEQ ID NO:1) can be modified and which ones are conserved such that one of skill in the art can make the recited polypeptides having the same biological activity as that of the polypeptide of SEQ ID NO:1 and having the properties recited in claims 1-2 and 4, (2) which segments of the polypeptide of SEQ ID NO:1 are essential for activity, and (3) the general tolerance of PQQGDH to structural modifications and the extent of such tolerance. The art clearly teaches that changes in a protein's amino acid sequence to obtain the desired activity without any guidance/knowledge as to which amino acids in a protein are required for that activity is highly unpredictable. At the time of the invention there was a high level of unpredictability associated with altering a polypeptide sequence with an expectation that the polypeptide will maintain the desired activity. For

example, Branden et al. (Introduction to Protein Structure, Garland Publishing Inc., New York, page 247, 1991 – form PTO-892) teach that (1) protein engineers are frequently surprised by the range of effects caused by single mutations that they hoped would change only one specific and simple property in enzymes, (2) the often surprising results obtained by experiments where single mutations are made reveal how little is known about the rules of protein stability, and (3) the difficulties in designing de novo stable proteins with specific functions.

The amount of direction or guidance presented and the existence of working examples.

The specification only enables specific PQQGH variants (Q168A+L169(G or P)+E245D) of a single PQQGDH having the amino acid sequence of SEQ ID NO:1, wherein said variants have the properties recited in claims 1-2 and 4. However, the specification fails to provide any information as to (1) specific substrates associated with the PQQGDH of SEQ ID NO:1, (2) structural elements required in a polypeptide having PQQGDH activity, or (3) which are the structural elements in the polypeptide of SEQ ID NO:1 that are essential to display PQQGDH activity or the properties recited in claims 1-2 and 4. No correlation between structure and function of having PQQGDH activity has been presented. There is no information or guidance as to which amino acid residues in the polypeptides of SEQ ID NO: 1 can be modified and which ones are to be conserved to create a polypeptide displaying the same activity as that of the polypeptides of SEQ ID NO:1 and display the properties recited in claims 1-2 and 4.

Thus, in view of the overly broad scope of the claims, the lack of guidance and working examples provided in the specification, the high level of unpredictability of the prior art in regard to structural changes and their effect on function and the lack of knowledge about a correlation between structure and function, an undue experimentation would be necessary one having ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated with the scope of the claims. The scope of the claims must bear a reasonable correlation with the scope of enablement (*In re Fisher*, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, determination of polypeptides having the desired biological characteristics recited in the claims are unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See *In re Wands* 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-2 and 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Morris et al.

Claims 1-2 and 4 are drawn to modified PQQGDH having lower action property on a disaccharide and/or more enhanced stability/specific activity than the wild type PQQGDH.

Sode et al. (US Patent No. 6,103,509 – cited previously on form PTO-892) discloses modified PQQGDH having less activity towards a disaccharide, increased specific activity towards glucose and increased stability compared to the wild-type PQQGDH (Column 2, lines 24-34, Table 1 and Column 4, lines 6-42). Since (1) there is no limitation on the structure of the modified PQQGDH and (2) the instant claims are drawn to a product, whose structure is not dependent on the limitation "assay system using ferricyanide ion as a mediator by the method according to claim 3, Examiner takes the position that the modified PQQGDH of Sode et al. reads on the instant claims. Therefore, the reference of Sode et al. anticipates claims 1-2 and 4.

Claims 1-2 and 4 are rejected under 35 U.S.C. 102(a) as being anticipated by Takeshima et al.

Claims 1-2 and 4 are drawn to modified PQQGDH having lower action property on a disaccharide and/or more enhanced stability/specific activity than the wild type PQQGDH.

Takeshima et al. (EP 1 367 120 A2 – form PTO-1449) discloses modified PQQGDH having less activity towards a disaccharide, increased specific activity towards glucose and increased stability compared to the wild-type PQQGDH (page 4). Since (1) there is no limitation on the structure of the modified PQQGDH and (2) the

Art Unit: 1652

instant claims are drawn to a product, whose structure is not dependent on the limitation "assay system using ferricyanide ion as a mediator by the method according to claim 3, Examiner takes the position that the modified PQQGDH of Takeshima et al. reads on the instant claims. Therefore, the reference of Takeshima et al. anticipates claims 1-2 and 4.

Applicant cannot rely upon the foreign priority papers to overcome this rejection because a translation of said papers has not been made of record in accordance with 37 CFR 1.55. See MPEP § 201.15.

Conclusion

Claims 1-2 and 4 are rejected.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 571-272-0935. The examiner can normally be reached 6:30 A.M. to 5:00 P.M. Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nashaat Nashed can be reached on 571-272-0934. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should

Art Unit: 1652

you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

/Yong D Pak/

Primary Examiner, Art Unit 1652